<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886494</url>
  </required_header>
  <id_info>
    <org_study_id>BAC-02</org_study_id>
    <nct_id>NCT02886494</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia</brief_title>
  <official_title>A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charsire Biotechnology Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charsire Biotechnology Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy
      and Safety of BAC in Patient with Alzheimer's Disease or Vascular Dementia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Alzheimer Disease Assessment Scale-cognitive (ADAS-cog) score at Week 12 visit compared to baseline</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ADAS-cog score at all post treatment visits (except Week 12 visit) compared to baseline</measure>
    <time_frame>Week 4, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician's Interview Based Impression of Change-Plus Caregiver Input (CIBIC-plus) score at all post treatment visits</measure>
    <time_frame>Week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) score at all post treatment visits compared to baseline</measure>
    <time_frame>Week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mini-Mental State Examination (MMSE) score at all post treatment visits compared to baseline</measure>
    <time_frame>Week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropsychiatric Inventory (NPI) score at all post treatment visits compared to baseline</measure>
    <time_frame>Week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event incidence</measure>
    <time_frame>Week 4, 8, 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alzheimer's Disease or Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>BAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAC</intervention_name>
    <arm_group_label>BAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched placebo</intervention_name>
    <arm_group_label>Matched vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. With either gender aged at least 40 years old

          2. With a diagnosis of one of the following disease i. Vascular dementia according to the
             NINDS-AIREN International Workshop criteria or ii. Alzheimer's disease according to
             the NIAAA criteria iii. &quot;Mixed&quot; dementia (possible Alzheimer's disease with
             cerebrovascular disease) according to the NIAAA criteria

             Note:

               1. NINDS-AIREN: National Institute of Neurological Disorders and Stroke and
                  Association Internationale pour la Recherche et l'Enseignement en Neurosciences

               2. NIAAA: National Institute on Aging-Alzheimer's Association

          3. With mild-to-moderate dementia (score of the Mini-Mental State Examination (MMSE)
             defined as between 10 to 24 and score of ADAS-Cog as at least 12)

          4. Able to read, write, communicate, and understand cognitive testing instructions

          5. Having a responsible caregiver who spends at least 4 hours daily with the patient. The
             caregiver will accompany the patient to all study visits, , supervise administration
             of study drug, and be able to assess the patient's condition

          6. Patients and the responsible caregiver willing and able to provide written informed
             consent form

        Exclusion Criteria:

          1. With large vessel thrombosis (thrombotic stroke occurring in large arteries)

          2. With radiological evidence of other brain disorders (subdural hematoma, post-traumatic
             / post-surgery)

          3. With dementia caused by other brain diseases except Alzheimer's disease and vascular
             dementia (e.g. Parkinson's disease, demyelinated disease of the central nervous
             system, tumor, hydrocephalus, head injury, central nervous system infection including
             syphilis, acquired immune deficiency syndrome, etc.)

          4. With clinical evidence of pulmonary, hepatic, gastrointestinal, metabolic, endocrine
             or other life threatening diseases judged by investigators not suitable to enter the
             study

          5. With clinically unstable hypertension, diabetes mellitus, and cardiac disease for the
             last 3 months

          6. Ever hospitalized for stroke or with acute coronary syndrome in the previous 3 months
             prior to screening

          7. Drug or alcohol abuse within the previous 12 months of screening.

          8. With one of the following abnormal laboratory parameters: hemoglobin &lt; 10 mg/dL or
             platelet &lt; 100*109/L; creatinine or total bilirubin more than 1.5 times the upper
             limit value; alanine aminotransferase (ALT), aspartate aminotransferase (AST),
             alkaline phosphates (ALP), γ-glutamyl transferase (γ-GT) more than 2 times the upper
             limit of normal, or thyroid-stimulating hormone (TSH) more than 2.5 times the upper
             limit value or less than the lower limit value of normal

          9. With severe depression graded by Diagnostic and Statistical Manual of Mental
             Disorders, Fifth Edition (DSM-5) and Cornell Scale for Depression in Dementia (CSDD)

         10. With any uncontrolled illness (including, but not limited to, any of the following:
             ongoing or active infection including hepatitis B, C, and HIV, active bleeding,
             symptomatic congestive heart failure, uncontrolled hypertension, unstable angina
             pectoris or, cardiac arrhythmia) judged by the investigator that entering the trial
             may be detrimental to the patient

         11. With known or suspected hypersensitivity to any ingredients of study product and
             vehicle

         12. Pregnant or lactating or premenopausal with childbearing potential but not taking
             reliable contraceptive method(s) during the study period

             Note: Reliable contraceptive methods will consider as below:

               1. Established use of oral, injected or implanted hormonal methods of contraception
                  &gt; 3 months prior to baseline.

               2. Placement of an intrauterine device (IUD) or intrauterine system (IUS) &gt; 3 months
                  prior to baseline.

               3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or
                  cervical/vault caps) with spermicidal foam/gel/film/cream/suppository

               4. Partner male sterilization (i.e., vasectomy) &gt; 1 month of screening

         13. Enrollment in any investigational drug trial within 4 weeks of screening visit

         14. Experienced dosage increment of routinely use in drugs listed as follows within past
             three months before Screening visit

               1. medications/treatments for Alzheimer's disease or vascular dementia

               2. antipsychotic medications including but not limited to selective serotonin
                  reuptake inhibitors (SSRIs), benzodiazepine (BZD)

               3. Vitamin B12

               4. drugs for thyroid disease

         15. Current antiplatelet drug (antiaggregant) except dosage including but not limited to
             aspirin &lt;= 100mg/day, clopidogrel &lt;= 75mg/day, ticagrelor &lt;= 180mg/day, dipyridamole
             &lt;= 400mg/day

         16. Caregivers who have psychotic symptoms, are imminently suicidal, have an unstable
             medical condition (e.g. recent heart attack, recent stroke, episodes of dizziness,
             fainting attacks) or significant orthopaedic problems.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Consortium</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Dean</last_name>
      <phone>602-910-3343</phone>
      <email>lisa.dean@crctrials.com</email>
    </contact>
    <investigator>
      <last_name>Corey Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Spencer</last_name>
      <phone>501-221-8681</phone>
      <email>hspencer@woodlandintlresearchgrp.com</email>
    </contact>
    <investigator>
      <last_name>George Konis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodland Research Northwest, LLC</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Frachiseur</last_name>
      <phone>479-927-3000</phone>
      <email>james@woodlandintlresearchgrp.com</email>
    </contact>
    <investigator>
      <last_name>Fayz Hudefi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network, LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bud Gaydos</last_name>
      <phone>619-294-4302</phone>
      <email>bgaydos@prnsd.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Thein, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Cognitive and Research Center of NJ</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kavita Doshi</last_name>
      <phone>973-850-4622</phone>
      <email>kdoshi@thecrcnj.com</email>
    </contact>
    <investigator>
      <last_name>Michelle Papka, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Memory Research Institute of NJ, PC</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryne Olsen</last_name>
      <phone>732-341-9500</phone>
      <email>rolsen@amrinj.com</email>
    </contact>
    <investigator>
      <last_name>Sanjiv Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SPRI</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Gutkin</last_name>
      <phone>718-616-2249</phone>
      <email>jgutkin@spristudy.com</email>
    </contact>
    <investigator>
      <last_name>Evgeny Fink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Peoples</last_name>
      <phone>919-781-2514</phone>
      <email>mpeoples@wakeresearch.com</email>
    </contact>
    <investigator>
      <last_name>Singar Jagadeesan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Diagnostics, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

